Payment overview · 2025
General Payments
$352.28
16 reported records · 8 companies
Healthcare provider profile · identity verified
Jonathan A Hatton, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · WHITESBURG, KY · NPI 1629362397
Verified facts
What the public records show
CMS Open Payments records show Jonathan A Hatton, D.O. received $352.28 in general payments during 2025 across 16 reported records.
Indivior Inc. accounted for 40.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Sublocade.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Kerendia by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Sublocade by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $143.50 | 40.7% | 7 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.43 | 14.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.34 | 12.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $43.78 | 12.4% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.09 | 6.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.32 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.38 | 4.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.44 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $352.28 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $143.50 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.43 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.34 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1370 | 193 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 673 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 351 | 62 |
| Pregabalin | Pregabalin | 333 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 267 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 219 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 216 | 47 |
| Lisinopril | Lisinopril | 210 | 54 |
| Ibuprofen | Ibuprofen | 203 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 201 | 32 |
| Famotidine | Famotidine | 200 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 186 | 45 |
| Montelukast Sodium | Montelukast Sodium | 171 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 43 |
| Ondansetron Odt | Ondansetron | 167 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 166 | 38 |
| Furosemide | Furosemide | 159 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 141 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 38 |
| Losartan Potassium | Losartan Potassium | 136 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 135 | 37 |
| Omeprazole | Omeprazole | 120 | 30 |
| Metformin Hcl | Metformin Hcl | 116 | 30 |
| Trazodone Hcl | Trazodone Hcl | 115 | 28 |
| Farxiga | Dapagliflozin Propanediol | 111 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 103 | 20 |
| Sertraline Hcl | Sertraline Hcl | 103 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 101 | 23 |
| Mirtazapine | Mirtazapine | 98 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 20 |
| Ozempic | Semaglutide | 97 | 18 |
| Carvedilol | Carvedilol | 95 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 24 |
| Potassium Chloride | Potassium Chloride | 83 | 29 |
| Promethazine Hcl | Promethazine Hcl | 83 | 25 |
| Clonazepam | Clonazepam | 80 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 17 |
| Mounjaro | Tirzepatide | 74 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 29 |
| Nifedipine Er | Nifedipine | 72 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 70 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 52 |
| Simvastatin | Simvastatin | 68 | 11 |
| Linzess | Linaclotide | 66 | 16 |
| Oxcarbazepine | Oxcarbazepine | 66 | 18 |
| Eliquis | Apixaban | 65 | 12 |
| Jardiance | Empagliflozin | 63 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 11 |
| Topiramate | Topiramate | 61 | 19 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 60 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 19 |
| Meloxicam | Meloxicam | 57 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 12 |
| Diltiazem 12hr Er | Diltiazem Hcl | 50 | 11 |
| Prednisone | Prednisone | 50 | 13 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Lamotrigine | Lamotrigine | 49 | 13 |
| Finasteride | Finasteride | 48 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | suppressed |
| Glipizide | Glipizide | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Constulose | Lactulose | 44 | 15 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | suppressed |
| Spironolactone | Spironolactone | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 11 |
| Sublocade | Buprenorphine | 39 | suppressed |
| Valsartan | Valsartan | 39 | 13 |
| Donepezil Hcl | Donepezil Hcl | 37 | 11 |
| Theophylline Er | Theophylline Anhydrous | 37 | suppressed |
| Nitroglycerin | Nitroglycerin | 36 | 12 |
| Atenolol | Atenolol | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Temazepam | Temazepam | 35 | 11 |
| Kerendia | Finerenone | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 26 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 15 |
| Methylprednisolone | Methylprednisolone | 32 | 27 |
| Propranolol Hcl | Propranolol Hcl | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Ibu | Ibuprofen | 30 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | 14 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 11 |
| Amoxicillin | Amoxicillin | 25 | 21 |
| Baclofen | Baclofen | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Belbuca | Buprenorphine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 17 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.28 · 16 records | Indivior Inc. | AIRSUPRA, CAPLYTA, FANAPT, HETLIOZ, JOURNAVX, Kerendia, SUBLOCADE, VOQUEZNA, ZERBAXA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error